Return to Today's science sparks archives

2020-04-01

Abstract. Clearing agents (CAs) can rapidly remove nonlocalized targeting biomolecules from circulation for hepatic catabolism, thereby enhancing the therapeutic index (TI), especially for blood (marrow), of the subsequently administered radioisotope in any multistep pretargeting strategy.

Abstract. Clearing agents (CAs) can rapidly remove nonlocalized targeting biomolecules from circulation for hepatic catabolism, thereby enhancing the therapeutic index (TI), especially for blood (marrow), of the subsequently administered radioisotope in any multistep pretargeting strategy.
  • Cheal SM, Patel M, Yang G, Veach D, Xu H, Guo HF, Zanzonico PB, Axworthy DB, Cheung NV, Ouerfelli O, Larson SM

  • Bioconjug Chem. 2020 Mar 18;31(3):501-506. doi: 10.1021/acs.bioconjchem.9b00736. Epub 2020 Feb 10.

2020-04-02

Fig 2. HLA-B leaders in HLA-B-mismatched unrelated donor transplantation.

Fig 2. HLA-B leaders in HLA-B-mismatched unrelated donor transplantation.
  • Petersdorf EW, Carrington M, O'hUigin C, Bengtsson M, De Santis D, Dubois V, Gooley T, Horowitz M, Hsu K, Madrigal JA, Maiers MJ, Malkki M, McKallor C, Morishima Y, Oudshoorn M, Spellman SR, Villard J, Stevenson P; International Histocompatibility Working Group in Hematopoietic Cell Transplantation

  • Lancet Haematol. 2020 Jan;7(1):e50-e60.

2020-04-03

Fig 1. Progression free and overall survival (PFS and OS) by regimen.

Fig 1. Progression free and overall survival (PFS and OS) by regimen.
  • Moore KN, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, O'Cearbhaill RE, Guntupalli SR, Armstrong DK, Hagemann AR, Gray HJ, Duska LR, Mathews CA, Chen A, O'Malley D, Gordon S, Fracasso PM, Aghajanian C

  • Gynecol Oncol. 2019 Nov 7. pii: S0090-8258(19)31569-0.

2020-04-06

Figure 1: Schematic illustration of the metabolomics-driven analysis strategy for the discovery of sex-related differences in colon cancer metabolism.

Figure 1: Schematic illustration of the metabolomics-driven analysis strategy for the discovery of sex-related differences in colon cancer metabolism.
  • Cai Y, Rattray NJW, Zhang Q, Mironova V, Santos-Neto A, Hsu KS, Rattray Z, Cross JR, Zhang Y, Paty PB, Khan SA, Johnson CH

  • Sci Rep. 2020 Mar 17;10(1):4905. doi: 10.1038/s41598-020-61851-0.
Open Access button

2020-04-07

Figure 1. Universal Approach Precautions to Screening and Oncologic Assessment for Patients on Opioid Therapy.

Figure 1. Universal Approach Precautions to Screening and Oncologic Assessment for Patients on Opioid Therapy.
  • Rodrigue D, Winkelmann J, Price M, Kalandranis E, Klempner L, Kapoor-Hintzen N

  • Clin J Oncol Nurs. 2020 Apr 1;24(2):170-176.

2020-04-08

Fig. 2. Factors perceived to influence the proportion of autologous reconstructions performed. OR, operating room; BMI, body mass index.

Fig. 2. Factors perceived to influence the proportion of autologous reconstructions performed. OR, operating room; BMI, body mass index.
  • Momoh AO, Griffith KA, Hawley ST, Morrow M, Ward KC, Hamilton AS, Shumway D, Katz SJ, Jagsi R

  • Plast Reconstr Surg. 2020 Apr;145(4):865-876.

2020-04-09

Graphical abstract.

Graphical abstract.
  • Murphy N, Carreras-Torres R, Song M, Chan AT, Martin RM, Papadimitriou N, Dimou N, Tsilidis KK, Banbury B, Bradbury KE, Besevic J, Rinaldi S, Riboli E, Cross AJ, Travis RC, Agnoli C, Albanes D, Berndt SI, Bezieau S, Bishop DT, Brenner H, Buchanan DD, Onland-Moret NC, Burnett-Hartman A, Campbell PT, Casey G, Castellvi-Bel S, Chang-Claude J, Chirlaque MD, de la Chapelle A, English D, Figueiredo JC, Gallinger SJ, Giles GG, Gruber SB, Gsur A, Hampe J, Hampel H, Harrison TA, Hoffmeister M, Hsu L, Huang WY, Huyghe JR, Jenkins MA, Keku TO, Kuhn T, Kweon SS, Le Marchand L, Li CI, Li L, Lindblom A, Martin V, Milne RL, Moreno V, Newcomb PA, Offit K, Ogino S, Ose J, Perduca V, Phipps AI, Platz EA, Potter JD, Qu C, Rennert G, Sakoda LC, Schafmayer C, Schoen RE, Slattery ML, Tangen CM, Ulrich CM, van Duijnhoven FJB, Van Guelpen B, Visvanathan K, Vodicka P, Vodickova L, Vymetalkova V, Wang H, White E, Wolk A, Woods MO, Wu AH, Zheng W, Peters U, Gunter MJ

  • Gastroenterology. 2020 Apr;158(5):1300-1312.e20. doi: 10.1053/j.gastro.2019.12.020. Epub 2019 Dec 27.

2020-04-10

Figure 2. Future directions for small molecule targeted inhibitors.

Figure 2. Future directions for small molecule targeted inhibitors.
  • Bedard PL, Hyman DM, Davids MS, Siu LL

  • Lancet. 2020 Mar 28;395(10229):1078-1088.

2020-04-13

Fig. 1. A-F The calibration curves of validation set data show the agreement between observed outcomes and those predicted by the (A) 1-month, (B) 3-month, (C) 6-month, (D) 12-month, (E) 18-month, and (F) 24-month PATHFx models.

Fig. 1. A-F The calibration curves of validation set data show the agreement between observed outcomes and those predicted by the (A) 1-month, (B) 3-month, (C) 6-month, (D) 12-month, (E) 18-month, and (F) 24-month PATHFx models.
  • Anderson AB, Wedin R, Fabbri N, Boland P, Healey J, Forsberg JA

  • Clin Orthop Relat Res. 2020 Apr;478(4):808-818. doi: 10.1097/CORR.0000000000001081.

2020-04-14

Fig 1. Overall survival of weaned and not weaned cancer patients.

Fig 1. Overall survival of weaned and not weaned cancer patients.
  • Haviland K, Tan KS, Schwenk N, Pillai MV, Stover DE, Downey RJ

  • BMC Palliat Care. 2020 Mar 30;19(1):42.
Open Access button

2020-04-15

Fig 1. Deletion of Cep83 disrupts DAPs and the anchorage of the centrosome to the membrane.

Fig 1. Deletion of Cep83 disrupts DAPs and the anchorage of the centrosome to the membrane.
  • Shao W, Yang J, He M, Yu XY, Lee CH, Yang Z, Joyner AL, Anderson KV, Zhang J, Tsou MB, Shi H, Shi SH

  • Nature. 2020 Apr;580(7801):106-112.

2020-04-16

Figure 1. Identification of Loss of Function ABCA1 Mutants in CMML

Figure 1. Identification of Loss of Function ABCA1 Mutants in CMML
  • Viaud M, Abdel-Wahab O, Gall J, Ivanov S, Guinamard R, Sore S, Merlin J, Ayrault M, Guilbaud E, Jacquel A, Auberger P, Wang N, Levine RL, Tall AR, Yvan-Charvet L.

  • Cell Rep, 30 (10), 3397-3410.e5

2020-04-17

Fig 1. Best percentage change from baseline in target lesions for patients with postbaseline assessments.

Fig 1. Best percentage change from baseline in target lesions for patients with postbaseline assessments.
  • Hellmann MD, Gettinger S, Chow LQM, Gordon M, Awad MM, Cha E, Gong X, Zhou G, Walker C, Leopold L, Heist RS

  • Int J Cancer. 2020 Mar 6.
Open Access button

2020-04-20

Fig. 1. The diagnosis of PTC is established by the presence of invasion.

Fig. 1. The diagnosis of PTC is established by the presence of invasion.
  • Rodrigo JP, Hernandez-Prera JC, Randolph GW, Zafereo ME, Hartl DM, Silver CE, Suarez C, Owen RP, Bradford CR, Makitie AA, Shaha AR, Bishop JA, Rinaldo A, Ferlito A

  • Cancer Treat Rev. 2020 Mar 19;86:102012.

2020-04-21

Figure 3: Correlation between PTHrP and phosphorus. PO, phosphorus; PTHrP, PTH-related peptide.

Figure 3: Correlation between PTHrP and phosphorus. PO, phosphorus; PTHrP, PTH-related peptide.
  • Chukir T, Liu Y, Hoffman K, Bilezikian JP, Farooki A

  • J Clin Endocrinol Metab. 2020 Apr 1;105(4). pii: 5679485. doi: 10.1210/clinem/dgz278.

2020-04-22

Fig 2. Diagram illustrating the stratified image sampling for the second readout (72 images total).

Fig 2. Diagram illustrating the stratified image sampling for the second readout (72 images total).
  • Becker AS, Jendele L, Skopek O, Berger N, Ghafoor S, Marcon M, Konukoglu E

  • Eur J Radiol. 2019 Sep 10;120:108649.

2020-04-24

Fig 1. Antitumor effects of enfortumab vedotin 1.25 mg/kg in patients with metastatic urothelial carcinoma.

Fig 1. Antitumor effects of enfortumab vedotin 1.25 mg/kg in patients with metastatic urothelial carcinoma.
  • Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, Heath EI, Merchan J, Quinn DI, Srinivas S, Milowsky M, Wu C, Gartner EM, Zuo P, Melhem-Bertrandt A, Petrylak DP

  • J Clin Oncol. 2020 Apr 1;38(10):1041-1049.
Open Access button

2020-04-27

Figure 1. Trametinib and Palbociclib Treatment Triggers Vascular Remodeling in PDAC.

Figure 1. Trametinib and Palbociclib Treatment Triggers Vascular Remodeling in PDAC.
  • Ruscetti M, Morris JP 4th, Mezzadra R, Russell J, Leibold J, Romesser PB, Simon J, Kulick A, Ho YJ, Fennell M, Li J, Norgard RJ, Wilkinson JE, Alonso-Curbelo D, Sridharan R, Heller DA, de Stanchina E, Stanger BZ, Sherr CJ, Lowe SW

  • Cell. 2020 Apr 16;181(2):424-441.e21. doi: 10.1016/j.cell.2020.03.008. Epub 2020 Mar 31.

2020-04-28

SI organoids recapitulate in vivo response to ionizing radiation.

SI organoids recapitulate in vivo response to ionizing radiation.
  • Martin ML, Adileh M, Hsu KS, Hua G, Lee SG, Li C, Fuller JD, Rotolo JA, Bodo S, Klingler S, Haimovitz-Friedman A, Deasy JO, Fuks Z, Paty PB, Kolesnick RN

  • Cancer Res. 2020 Mar 1;80(5):1219-1227.

2020-04-28

Figure 2. K562 Knockout Cells Recapitulate Dependency of mir-451 on mir-144.

Figure 2. K562 Knockout Cells Recapitulate Dependency of mir-451 on mir-144.
  • Shang R, Baek SC, Kim K, Kim B, Kim VN, Lai EC

  • Mol Cell. 2020 Apr 16;78(2):303-316.e4. doi: 10.1016/j.molcel.2020.02.009.

2020-04-29

Fig 5. A model of AR binding to DNA in the context of ERG.

Fig 5. A model of AR binding to DNA in the context of ERG.
  • Wasmuth EV, Hoover EA, Antar A, Klinge S, Chen Y, Sawyers CL

  • Proc Natl Acad Sci U S A. 2020 Apr 14;117(15):8584-8592. doi: 10.1073/pnas.1922159117. Epub 2020 Mar 27.
Open Access button

2020-04-30

FIGURE 1. Adjusted rates of continent cutaneous urinary diversion (solid line, P < 0.0001), ileal conduit urinary diversion (dotted line, P < 0.0001) and orthotopic neobladder (dashed line, P < 0.0001), by year of radical cystectomy, among 2911 patients with urothelial carcinoma undergoing radical cystectomy at Memorial Sloan Kettering Cancer Center from 1995 to 2015. Rates are adjusted for age.

FIGURE 1. Adjusted rates of continent cutaneous urinary diversion (solid line, P < 0.0001), ileal conduit urinary diversion (dotted line, P < 0.0001) and orthotopic neobladder (dashed line, P < 0.0001), by year of radical cystectomy, among 2911 patients with urothelial carcinoma undergoing radical cystectomy at Memorial Sloan Kettering Cancer Center from 1995 to 2015. Rates are adjusted for age.
  • Almassi N, Bochner BH

  • Curr Opin Urol. 2020 May;30(3):415-420. doi: 10.1097/MOU.0000000000000738.

2020-05-01

Fig 1.  Representative tissue microarray cores showing STAT1 immunohistochemical staining.

Fig 1. Representative tissue microarray cores showing STAT1 immunohistochemical staining.
  • Tanaka A, Zhou Y, Ogawa M, Shia J, Klimstra DS, Wang JY, Roehrl MH

  • PLoS One. 2020 Apr 10;15(4):e0229252. doi: 10.1371/journal.pone.0229252. eCollection 2020.
Open Access button

2020-05-04

Fig 1. Representative immunohistochemistry images demonstrating CD4+ (upper), IL-4+ (middle), and IL-13+ (lower) cells in matched human biopsy specimens comparing lymphedematous and contralateral normal upper extremities.

Fig 1. Representative immunohistochemistry images demonstrating CD4+ (upper), IL-4+ (middle), and IL-13+ (lower) cells in matched human biopsy specimens comparing lymphedematous and contralateral normal upper extremities.
  • Li CY, Kataru RP, Mehrara BJ

  • Int J Mol Sci. 2020 Apr 6;21(7). pii: ijms21072546. doi: 10.3390/ijms21072546.
Open Access button

2020-05-05

Fig. 8. Single-cell expansion model for melphalan and GC-related mutational signatures.

Fig. 8. Single-cell expansion model for melphalan and GC-related mutational signatures.
  • Rustad EH, Yellapantula V, Leongamornlert D, Bolli N, Ledergor G, Nadeu F, Angelopoulos N, Dawson KJ, Mitchell TJ, Osborne RJ, Ziccheddu B, Carniti C, Montefusco V, Corradini P, Anderson KC, Moreau P, Papaemmanuil E, Alexandrov LB, Puente XS, Campo E, Siebert R, Avet-Loiseau H, Landgren O, Munshi N, Campbell PJ, Maura F

  • Nat Commun. 2020 Apr 21;11(1):1917.

2020-05-06

Fig 5. XPO5 associates with diverse cellular RNAs.

Fig 5. XPO5 associates with diverse cellular RNAs.
  • Wang J, Lee JE, Riemondy K, Yu Y, Marquez SM, Lai EC, Yi R

  • Nat Commun. 2020 Apr 15;11(1):1845.
Open Access button

2020-05-07

Fig. 2. Example for a lesion that could be downgraded by second-look ultrasound.

Fig. 2. Example for a lesion that could be downgraded by second-look ultrasound.
  • Kolta M, Clauser P, Kapetas P, Bernathova M, Pinker K, Helbich TH, Baltzer PAT

  • Eur J Radiol. 2020 Apr 11;127:108976.

2020-05-08

FIGURE 3. Case 5. A, Hematoxylin and eosin-stained section of case diagnosed as mixed endometrioid/serous carcinoma. Pictured here is the serous component showing focal papillary architecture, high nuclear grade, and prominent nucleoli. B, Loss of PTEN by immunohistochemistry. C, Aberrant p53 over-expression by immunohistochemistry.

FIGURE 3. Case 5. A, Hematoxylin and eosin-stained section of case diagnosed as mixed endometrioid/serous carcinoma. Pictured here is the serous component showing focal papillary architecture, high nuclear grade, and prominent nucleoli. B, Loss of PTEN by immunohistochemistry. C, Aberrant p53 over-expression by immunohistochemistry.
  • Conlon N, Da Cruz Paula A, Ashley CW, Segura S, De Brot L, da Silva EM, Soslow RA, Weigelt B, DeLair DF

  • Am J Surg Pathol. 2020 May;44(5):641-648.

2020-05-11

FIGURE 2. In vitro vessel tracking experiments.

FIGURE 2. In vitro vessel tracking experiments.
  • Sartoretti T, van Smoorenburg L, Sartoretti E, Schwenk A, Binkert CA, Kulcsar Z, Becker AS, Graf N, Wyss M, Sartoretti-Schefer S

  • Invest Radiol. 2020 May;55(5):293-303. doi: 10.1097/RLI.0000000000000641.

2020-05-12

Figure 2. Results of training (A), validation (B), and analytical sensitivity (C) studies.

Figure 2. Results of training (A), validation (B), and analytical sensitivity (C) studies.
  • Benhamida JK, Hechtman JF, Nafa K, Villafania L, Sadowska J, Wang J, Wong D, Zehir A, Zhang L, Bale T, Arcila ME, Ladanyi M

  • J Mol Diagn, 22 (3), 368-375.

2020-05-13

Fig 1. Clonality of normal endometrial glands.

Fig 1. Clonality of normal endometrial glands.
  • Moore L, Leongamornlert D, Coorens THH, Sanders MA, Ellis P, Dentro SC, Dawson KJ, Butler T, Rahbari R, Mitchell TJ, Maura F, Nangalia J, Tarpey PS, Brunner SF, Lee-Six H, Hooks Y, Moody S, Mahbubani KT, Jimenez-Linan M, Brosens JJ, Iacobuzio-Donahue CA, Martincorena I, Saeb-Parsy K, Campbell PJ, Stratton MR

  • Nature. 2020 Apr;580(7805):640-646.

2020-05-14

Fig 1.  Mechanisms of regulatory T (Treg) cell suppression.

Fig 1.  Mechanisms of regulatory T (Treg) cell suppression.
  • Plitas G, Rudensky AY

  • Annual Review of Cancer Biology 2020 4:1, 459-477
Open Access button

2020-05-15

Extended Data Fig. 2. Expression and co-expression of SARS-CoV-2 entry-associated proteases in ACE2+ airway epithelial cells.

Extended Data Fig. 2. Expression and co-expression of SARS-CoV-2 entry-associated proteases in ACE2+ airway epithelial cells.
  • Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, Talavera-López C, Maatz H, Reichart D, Sampaziotis F, Worlock KB, Yoshida M, Barnes JL, HCA Lung Biological Network

  • Nat Med. 2020 Apr 23.

2020-05-18

Fig 7. Sox2 directly binds to the miR-486-5p promoter to activate expression in GBM neurospheres.

Fig 7. Sox2 directly binds to the miR-486-5p promoter to activate expression in GBM neurospheres.
  • Lopez-Bertoni H, Kotchetkov IS, Mihelson N, Lal B, Rui Y, Ames H, Lugo-Fagundo M, Guerrero-Cazares H, Quinones-Hinojosa A, Green JJ, Laterra J

  • Cancer Res. 2020 Apr 15;80(8):1644-1655. doi: 10.1158/0008-5472.CAN-19-1624. Epub 2020 Feb 24.
Open Access button

2020-05-19

Figure 1. Innate immune regulation of antiviral defense and tissue toxicity. Virally derived DAMPs and PAMPs activate tissue-resident macrophages.

Figure 1. Innate immune regulation of antiviral defense and tissue toxicity. Virally derived DAMPs and PAMPs activate tissue-resident macrophages.
  • Vardhana SA, Wolchok JD

  • J Exp Med. 2020 Jun 1;217(6). pii: 151725. doi: 10.1084/jem.20200678.
Open Access button

2020-05-20

Figure 1. Relocation of Collapsed Forks to the NPC Depends on Slx5 SUMO-Interacting Motif (SIM) Domains and Mms21-Mediated Sumoylation.

Figure 1. Relocation of Collapsed Forks to the NPC Depends on Slx5 SUMO-Interacting Motif (SIM) Domains and Mms21-Mediated Sumoylation.
  • Whalen JM, Dhingra N, Wei L, Zhao X, Freudenreich CH

  • Cell Rep. 2020 May 12;31(6):107635. doi: 10.1016/j.celrep.2020.107635.
Open Access button

2020-05-21

Figure 5. Postoperative T1-weighted MRI in axial (left) and coronal (right) views showing no remnant or residual cyst.

Figure 5. Postoperative T1-weighted MRI in axial (left) and coronal (right) views showing no remnant or residual cyst.
  • Lara-Reyna JJ, Uribe-Cardenas R, Perera I, Szerlip N, Giamouriadis A, Savage N, Haussner T, Souweidane MM

  • J Neurosurg. 2019 Apr 12:1-6. doi: 10.3171/2018.12.JNS181859.
Open Access button

2020-05-22

Figure 2. Representative late gadolinium enhancement pattern.

Figure 2. Representative late gadolinium enhancement pattern.
  • Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, Zlotoff DA, Murphy SP, Stone JR, Golden DLA, Alvi RM, Rokicki A, Jones-O'Connor M, Cohen JV, Heinzerling LM, Mulligan C, Armanious M, Barac A, Forrestal BJ, Sullivan RJ, Kwong RY, Yang EH, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Coelho-Filho OR, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Mercurio V, Mahmoudi M, Lawrence DP, Reynolds KL, Weinsaft JW, Baksi AJ, Ederhy S, Groarke JD, Lyon AR, Fradley MG, Thavendiranathan P, Neilan TG

  • Eur Heart J. 2020 May 7;41(18):1733-1743. doi: 10.1093/eurheartj/ehaa051.
Open Access button

2020-05-26

Fig 1. (A) Overall survival (OS) from the start of the first cycle of treatment by Kaplan-Meier estimation with 95% CIs (n = 29). (B) Landmark analysis of OS after completion of 2 cycles of treatment, according to hematologic response category: complete response, very good partial response, or partial response (CR/VGPR/PR) versus stable disease/progression of disease (SD/PD).

Fig 1. (A) Overall survival (OS) from the start of the first cycle of treatment by Kaplan-Meier estimation with 95% CIs (n = 29). (B) Landmark analysis of OS after completion of 2 cycles of treatment, according to hematologic response category: complete response, very good partial response, or partial response (CR/VGPR/PR) versus stable disease/progression of disease (SD/PD).
  • Lentzsch S, Lagos GG, Comenzo RL, Zonder JA, Osman K, Pan S, Bhutani D, Pregja S, Sanchorawala V, Landau H

  • J Clin Oncol. 2020 May 1;38(13):1455-1462.

2020-05-27

Fig. 2. (A) Transcervical access with catheter near the leak; green arrow = transected end of cranial portion of the thoracic duct; red arrow = microcatheter tip within the leak; blue bracket = extravasated contrast. (B) Following transcervical TDE; green bracket = glue within the cranial portion of the thoracic duct.

Fig. 2. (A) Transcervical access with catheter near the leak; green arrow = transected end of cranial portion of the thoracic duct; red arrow = microcatheter tip within the leak; blue bracket = extravasated contrast. (B) Following transcervical TDE; green bracket = glue within the cranial portion of the thoracic duct.
  • Drabkin M, Maybody M, Solomon N, Kishore S, Santos E

  • Radiol Case Rep. 2020 May 7;15(7):929–32.
Open Access button

2020-05-28

Fig. 3 Serum REG3α levels and correlates with nonrelapse mortality in patients with GI GVHD.

Fig. 3 Serum REG3α levels and correlates with nonrelapse mortality in patients with GI GVHD.
  • Zhao D, Kim YH, Jeong S, Greenson JK, Chaudhry MS, Hoepting M, Anderson ER, van den Brink MR, Peled JU, Gomes AL, Slingerland AE, Donovan MJ, Harris AC, Levine JE, Ozbek U, Hooper LV, Stappenbeck TS, Ver Heul A, Liu TC, Reddy P, Ferrara JL

  • J Clin Invest. 2018 Nov 1;128(11):4970-4979.
Open Access button

2020-05-29

Fig 1. iCRISPR leads to efficient genome editing within the adult pancreas.

Fig 1. iCRISPR leads to efficient genome editing within the adult pancreas.
  • Mishra A, Emamgholi F, Erlangga Z, Hartleben B, Unger K, Wolff K, Teichmann U, Kessel M, Woller N, Kuhnel F, Dow LE, Manns MP, Vogel A, Lowe SW, Saborowski A, Saborowski M

  • Carcinogenesis. 2020 May 14;41(3):334-344. doi: 10.1093/carcin/bgz108.
Open Access button

2020-06-01

Fig 1. tDCS montage with modeled current density for left dlPFC stimulation.

Fig 1. tDCS montage with modeled current density for left dlPFC stimulation.
  • Gaynor AM, Pergolizzi D, Alici Y, Ryan E, McNeal K, Ahles TA, Root JC

  • Brain Stimul. 2020 Apr 27;13(4):1108-1116. doi: 10.1016/j.brs.2020.04.013.
Open Access button

2020-06-02

Figure 2. Benefits of mentoring.

Figure 2. Benefits of mentoring.
  • Miller C, Wagenberg C, Loney E, Porinchak M, Ramrup N

  • J Nurs Adm. 2020 Jun;50(6):343-348. doi: 10.1097/NNA.0000000000000895.

2020-06-03

Fig. 2. A diagrammatic representation of the eight proteins known to be involved in cell cycle regulation, the complex is designated as S-phase complex.

Fig. 2. A diagrammatic representation of the eight proteins known to be involved in cell cycle regulation, the complex is designated as S-phase complex.
  • Jhanwar SC, Xu XL, Elahi AH, Abramson DH

  • Adv Biol Regul. 2020;78:100723.

2020-06-04

Graphical Abstract.

Graphical Abstract.
  • Abe T, Inoue KI, Furuta Y, Kiyonari H

  • Cell Rep. 2020 May 19;31(7):107653. doi: 10.1016/j.celrep.2020.107653.
Open Access button

2020-06-05

Figure 1 Time to ≥ grade 2 radiation pneumonitis (RP2) in the concurrent chemoradiation alone cohort (cCRT, grey circles) and in the concurrent chemoradiation and consolidative durvalumab cohort (cCRT + durvalumab cohort, orange circles) as well as their cohort median time to RP2 (dashed grey and dashed orange lines, respectively).

Figure 1 Time to ≥ grade 2 radiation pneumonitis (RP2) in the concurrent chemoradiation alone cohort (cCRT, grey circles) and in the concurrent chemoradiation and consolidative durvalumab cohort (cCRT + durvalumab cohort, orange circles) as well as their cohort median time to RP2 (dashed grey and dashed orange lines, respectively).
  • Shaverdian N, Thor M, Shepherd AF, Offin MD, Jackson A, Wu AJ, Gelblum DY, Yorke ED, Simone CB 2nd, Chaft JE, Hellmann MD, Gomez DR, Rimner A, Deasy JO

  • Cancer Med. 2020 May 6. doi: 10.1002/cam4.3113.
Open Access button

2020-06-08

Fig 1. Genetic heterogeneity of immune cells and pseudo-diploid cells in breast cancer biopsies.

Fig 1. Genetic heterogeneity of immune cells and pseudo-diploid cells in breast cancer biopsies.
  • Baslan T, Kendall J, Volyanskyy K, McNamara K, Cox H, D'Italia S, Ambrosio F, Riggs M, Rodgers L, Leotta A, Song J, Mao Y, Wu J, Shah R, Gularte-Merida R, Chadalavada K, Nanjangud G, Varadan V, Gordon A, Curtis C, Krasnitz A, Dimitrova N, Harris L, Wigler M, Hicks J

  • Elife. 2020 May 13;9. pii: 51480. doi: 10.7554/eLife.51480.
Open Access button

2020-06-09

FIG 1. Mechanisms of immune evasion of neuroblastoma (NB).

FIG 1. Mechanisms of immune evasion of neuroblastoma (NB).
  • Park JA, Cheung NV

  • J Clin Oncol. 2020 Jun 1;38(16):1836-1848.
Open Access button

2020-06-10

Fig. 2. Atypical melanocytic proliferation from the ear of an elderly man.

Fig. 2. Atypical melanocytic proliferation from the ear of an elderly man.
  • Crompton JG, Busam KJ, Bartlett EK

  • Surg Oncol Clin N Am. 2020 Jul;29(3):327-338.

2020-06-11

FIGURE 2. MRI brain with and without contrast November 2014 (A–E).

FIGURE 2. MRI brain with and without contrast November 2014 (A–E).
  • Malhotra A, Latov N

  • J Clin Neuromuscul Dis. 2020 Jun;21(4):225-229.

2020-06-12

Fig 3: Glycation of DNA/RNA (A), histones (B), transcription factors (C), and its corresponding consequences in epigenetic regulation.

Fig 3: Glycation of DNA/RNA (A), histones (B), transcription factors (C), and its corresponding consequences in epigenetic regulation.
  • Zheng Q, Maksimovic I, Upad A, David Y

  • Protein Cell. 2020 Jun;11(6):401-416. doi: 10.1007/s13238-020-00722-w. Epub 2020 Apr 30.
Open Access button

2020-06-15

Fig. 6: Single-point mutations in POPS are sufficient to cause replication defects and GCR increase.

Fig. 6: Single-point mutations in POPS are sufficient to cause replication defects and GCR increase.
  • Meng X, Wei L, Devbhandari S, Zhang T, Xiang J, Remus D, Zhao X

  • Nat Commun. 2020 May 15;11(1):2437. doi: 10.1038/s41467-020-16095-x.
Open Access button

2020-06-16

Figure 2. (A) Stack‐of‐stars golden‐angle radial sampling for MRSIGMA. (B) High temporal resolution signature data are generated by taking a fast Fourier transform along the z‐dimension for each rotating angle to generate projections.

Figure 2. (A) Stack‐of‐stars golden‐angle radial sampling for MRSIGMA. (B) High temporal resolution signature data are generated by taking a fast Fourier transform along the z‐dimension for each rotating angle to generate projections.
  • Feng L, Tyagi N, Otazo R

  • Magn Reson Med. 2020 Sep;84(3):1280-1292.

2020-06-17

Fig. 9 Surviving fraction and karyotype diversity index K, for the full model with N = 8 and the standard parameters.

Fig. 9 Surviving fraction and karyotype diversity index K, for the full model with N = 8 and the standard parameters.
  • Elizalde S, Laughney AM, Bakhoum SF

  • PLoS Comput Biol. 2018 Sep 11;14(9):e1006447.
Open Access button

2020-06-18

Fig. 3. Focal strong immunohistochemical labeling for p53 did not reach the overall threshold for abnormal staining in this case (4) with a TP53 mutation.

Fig. 3. Focal strong immunohistochemical labeling for p53 did not reach the overall threshold for abnormal staining in this case (4) with a TP53 mutation.
  • Attiyeh M, Zhang L, Iacobuzio-Donahue C, Allen P, Imam R, Basturk O, Klimstra DS, Sigel CS

  • Hum Pathol. 2020 May 5;101:1-9.

2020-06-19

Fig 1. MAP3K1 alterations are associated with improved clinical benefit to PI3Ki and endocrine therapy in PIK3CAMUT ER+ breast cancers.

Fig 1. MAP3K1 alterations are associated with improved clinical benefit to PI3Ki and endocrine therapy in PIK3CAMUT ER+ breast cancers.
  • Nixon MJ, Formisano L, Mayer IA, Estrada MV, González-Ericsson PI, Isakoff SJ, Forero-Torres A, Won H, Sanders ME, Solit DB, Berger MF, Cantley LC, Winer EP, Arteaga CL, Balko JM

  • NPJ Breast Cancer. 2019 Sep 23;5:31. doi: 10.1038/s41523-019-0126-6. eCollection 2019.
Open Access button

2020-06-22

Fig 5. ATM and KIAA0930 isoforms.

Fig 5. ATM and KIAA0930 isoforms.
  • Ji X, Mukherjee S, Landi MT, Bosse Y, Joubert P, Zhu D, Gorlov I, et al.

  • Nat Commun. 2020 May 11;11(1):2220. doi: 10.1038/s41467-020-15905-6.
Open Access button

2020-06-23

FIGURE 1. A and B, Nevoid melanoma, H&E stain. C and D, Diffuse (4+) PRAME immunoreactivity. E, SNP-array showing multiple aberrations including loss of chromosome 3, segmental loss in 5q, segmental loss in 9p, segmental losses in 11p, segmental loss in 11q, loss of chromosome 21.

FIGURE 1. A and B, Nevoid melanoma, H&E stain. C and D, Diffuse (4+) PRAME immunoreactivity. E, SNP-array showing multiple aberrations including loss of chromosome 3, segmental loss in 5q, segmental loss in 9p, segmental losses in 11p, segmental loss in 11q, loss of chromosome 21.
  • Lezcano C, Jungbluth AA, Busam KJ

  • Am J Surg Pathol. 2020 Jul;44(7):893-900. doi: 10.1097/PAS.0000000000001492.

2020-06-24

Figure 1. Posterior intercostal lymph nodes.

Figure 1. Posterior intercostal lymph nodes.
  • Friedberg JS, Simone CB 2nd, Culligan MJ, Putt ME, Barsky AR, Katz S, Cengel KA

  • Ann Thorac Surg. 2020 Jul;110(1):241-250. doi: 10.1016/j.athoracsur.2019.07.097. Epub 2019 Oct 18.

2020-06-25

Figure 5: Downregulation of PCDH9 by miR-1260b in NFs promotes MFS cell invasion.

Figure 5: Downregulation of PCDH9 by miR-1260b in NFs promotes MFS cell invasion.
  • Morita T, Fujiwara T, Yoshida A, Uotani K, Kiyono M, Yokoo S, Hasei J, Kunisada T, Ozaki T

  • Sci Rep. 2020 Jun 10;10(1):9414. doi: 10.1038/s41598-020-66120-8.
Open Access button

2020-06-26

Fig. 1. (a–c) Examples of imaging features measured on CT.

Fig. 1. (a–c) Examples of imaging features measured on CT.
  • Hotker AM, Karlo CA, Di Paolo PL, Zheng J, Moskowitz CS, Russo P, Hricak H, Akin O

  • Eur J Radiol. 2020 May 30;129:109096. doi: 10.1016/j.ejrad.2020.109096.
Open Access button

2020-06-29

Fig 2. Overlap of loci identified by primary and secondary analyses.

Fig 2. Overlap of loci identified by primary and secondary analyses.
  • Landi MT, Bishop DT, MacGregor S,...Law MH

  • Nat Genet. 2020 May;52(5):494-504.

2020-06-30

Pharmacophore-specific condensates.

Pharmacophore-specific condensates.
  • Viny AD, Levine RL

  • Science. 2020 Jun 19;368(6497):1314-1315. doi: 10.1126/science.abc5318.

2020-07-01

Fig 1. Domain architecture of the NLRP1 inflammasome proteins.

Fig 1. Domain architecture of the NLRP1 inflammasome proteins.
  • Taabazuing CY, Griswold AR, Bachovchin DA

  • Immunol Rev. 2020 Jun 19. doi: 10.1111/imr.12884.
Open Access button